Twist Bioscience Corp
TWST
26.99USD+0.58Â (+2.20%)Market ClosedWatchlist
Market Summary
USD26.99+0.58
Market Closed2.20%
TWST Alerts
TWST Stock Price
View Fullscreen
TWST RSI Chart
TWST Alerts
TWST Valuation
TWST Price/Sales (Trailing)
TWST Profitability
TWST Fundamentals
TWST Revenue
TWST Earnings
Price Action
Last 7 days
8.9%
Last 30 days
55.1%
Last 90 days
20.4%
Trailing 12 Months
2.5%
How does TWST drawdown profile look like?
TWST Financial Health
TWST Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 227.8M | 235.5M | 245.1M | 0 |
| 2022 | 163.1M | 184.2M | 203.6M | 215.8M |
| 2021 | 113.0M | 126.8M | 132.3M | 146.2M |
| 2020 | 65.8M | 73.4M | 90.1M | 101.1M |
| 2019 | 40.0M | 47.1M | 54.4M | 60.1M |
| 2018 | 18.1M | 21.8M | 25.4M | 32.6M |
| 2017 | 0 | 0 | 10.8M | 14.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TWST
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Dec 05, 2023 | werner robert f. | sold (taxes) | -3,725 | 24.67 | -151 | chief accounting officer |
| Dec 05, 2023 | green paula | sold (taxes) | -22,943 | 24.67 | -930 | svp of human resources |
| Dec 05, 2023 | cho dennis | sold (taxes) | -6,414 | 24.67 | -260 | see remarks |
| Dec 05, 2023 | banyai william | sold (taxes) | -19,119 | 24.67 | -775 | see remarks |
| Dec 05, 2023 | leproust emily m. | sold (taxes) | -57,456 | 24.67 | -2,329 | chief executive officer |
| Nov 20, 2023 | banyai william | sold (taxes) | -23,948 | 24.74 | -968 | see remarks |
| Nov 20, 2023 | leproust emily m. | sold (taxes) | -65,857 | 24.74 | -2,662 | chief executive officer |
| Nov 20, 2023 | thorburn james m | sold (taxes) | -25,432 | 24.74 | -1,028 | chief financial officer |
| Nov 20, 2023 | green paula | sold (taxes) | -9,228 | 24.74 | -373 | svp of human resources |
| Nov 20, 2023 | finn patrick john | sold (taxes) | -25,432 | 24.74 | -1,028 | president and coo |
Which funds bought or sold TWST recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | CITIGROUP INC | added | 94.12 | 2,568,040 | 5,352,770 | -% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 4.85 | 38,208 | 1,037,480 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | new | - | 304,203 | 304,203 | 0.01% |
| Nov 21, 2023 | COMERICA BANK | new | - | 46,395 | 46,395 | -% |
| Nov 16, 2023 | Financial Gravity Asset Management, Inc. | reduced | -90.00 | -96.00 | 31.00 | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 11.5 | 102,365 | 1,085,750 | -% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | sold off | -100 | -575,990 | - | -% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | reduced | -38.45 | -1,035,910 | 1,616,890 | -% |
| Nov 15, 2023 | Capital Impact Advisors, LLC | added | 8.95 | 68,242 | 933,925 | 1.56% |
| Nov 15, 2023 | MORGAN STANLEY | added | 22.69 | 4,006,520 | 22,645,400 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Twist Bioscience Corp
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 08, 2023 | integrated core strategies (us) llc | 5.3% | 3,042,960 | SC 13G | |
| Apr 10, 2023 | vanguard group inc | 10.02% | 5,697,547 | SC 13G/A | |
| Apr 06, 2023 | blackrock inc. | 10.9% | 6,212,913 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 1.2% | 704,000 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.24% | 5,229,345 | SC 13G/A | |
| Feb 03, 2023 | state street corp | 7.82% | 4,426,249 | SC 13G | |
| Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 5.18% | 2,934,033 | SC 13G | |
| Jan 24, 2023 | blackrock inc. | 9.7% | 5,487,180 | SC 13G/A | |
| Jan 13, 2023 | jpmorgan chase & co | 6.7% | 3,829,962 | SC 13G |
Recent SEC filings of Twist Bioscience Corp
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Dec 07, 2023 | 4 | Insider Trading | |
| Dec 07, 2023 | 4 | Insider Trading | |
| Dec 07, 2023 | 4 | Insider Trading | |
| Dec 07, 2023 | 4 | Insider Trading | |
| Dec 07, 2023 | 4 | Insider Trading | |
| Nov 22, 2023 | 4 | Insider Trading | |
| Nov 22, 2023 | 4 | Insider Trading | |
| Nov 22, 2023 | 4 | Insider Trading | |
| Nov 22, 2023 | 4 | Insider Trading | |
| Nov 22, 2023 | 4 | Insider Trading |
Peers (Alternatives to Twist Bioscience Corp)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 160.7B | 29.6B | 10.51% | -19.98% | 27.16 | 5.44 | -5.39% | -12.54% |
IDXX | 44.1B | 3.6B | 24.23% | 23.99% | 53.65 | 12.3 | 7.43% | 22.86% |
A | 37.3B | 7.0B | 16.28% | -18.61% | 32.89 | 5.33 | 5.03% | -14.68% |
DGX | 15.2B | 9.3B | 1.84% | -9.68% | 19.95 | 1.64 | -9.69% | -38.22% |
EXAS | 11.7B | 2.4B | 2.99% | 40.82% | -41.48 | 4.86 | 19.99% | 60.62% |
| MID-CAP | ||||||||
CRL | 10.5B | 4.2B | 16.20% | -2.67% | 22.08 | 2.49 | 11.49% | 8.84% |
MEDP | 8.7B | 1.8B | 2.84% | 34.94% | 31.81 | 4.88 | 29.62% | 20.49% |
NTRA | 6.9B | 988.7M | 40.66% | 50.03% | -13.86 | 7 | 27.41% | 8.51% |
NEOG | 3.9B | 919.1M | 17.21% | 17.06% | -147.97 | 4.28 | 73.02% | -172.93% |
GH | 3.0B | 535.8M | 8.75% | -45.64% | -7.02 | 5.66 | 24.38% | 26.34% |
| SMALL-CAP | ||||||||
CDNA | 531.2M | 297.1M | 54.98% | -22.82% | -5.87 | 1.79 | -6.74% | -21.60% |
ACRS | 71.5M | 21.4M | -81.47% | -93.49% | -0.62 | 3.34 | -8.80% | -39.66% |
AWH | 31.2M | 9.2M | -11.33% | -33.68% | -1.76 | 3.4 | 16.43% | 48.38% |
APDN | 12.0M | 13.4M | -4.35% | -39.31% | -1.21 | 0.9 | -26.43% | -20.54% |
BIOC | 120.4K | - | -82.76% | -93.43% | 0 | 0.76 | -57.78% | -93.13% |
Twist Bioscience Corp News
Latest updates
Financials for Twist Bioscience Corp
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 5.0% | 66,946,000 | 63,740,000 | 60,180,000 | 54,243,000 | 57,306,500 | 56,113,000 | 48,127,000 | 42,018,000 | 37,950,500 | 35,018,000 | 31,204,000 | 28,161,000 | 32,432,000 | 21,207,000 | 19,297,000 | 17,164,000 | 15,736,500 | 13,600,000 | 13,557,000 | 11,492,000 | 8,407,000 |
| Cost Of Revenue | 1.4% | 42,424,000 | 41,845,000 | 41,669,000 | 29,442,000 | 31,586,000 | 30,974,000 | 29,714,000 | 27,056,000 | 22,497,000 | 20,933,000 | 19,028,000 | 18,162,000 | 17,577,500 | 16,472,000 | 13,564,000 | 13,792,000 | 12,385,500 | 11,394,000 | 11,789,000 | 11,857,000 | 9,093,000 |
| Costs and Expenses | -6.0% | 117,057,500 | 124,521,000 | 121,817,000 | 98,873,000 | 114,177,500 | 117,276,000 | 108,929,000 | 97,958,000 | 77,761,500 | 77,136,000 | 69,208,000 | 60,954,000 | 56,399,000 | 49,403,000 | 51,383,000 | 72,994,000 | 47,305,000 | 41,721,000 | 39,820,000 | 34,389,000 | 28,111,000 |
| S&GA Expenses | 2.9% | 47,391,500 | 46,057,000 | 53,965,000 | 42,324,000 | 54,159,500 | 53,693,000 | 53,998,000 | 51,098,000 | 38,242,500 | 34,478,000 | 34,389,000 | 28,792,000 | 27,185,000 | 22,487,000 | 27,190,000 | 26,405,000 | 24,423,000 | 21,320,000 | 19,124,000 | 15,259,000 | 12,953,000 |
| R&D Expenses | -3.2% | 23,745,500 | 24,528,000 | 27,379,000 | 31,242,000 | 29,606,000 | 36,840,000 | 31,231,000 | 22,630,000 | 19,443,000 | 19,838,000 | 15,791,000 | 14,000,000 | 11,636,500 | 10,444,000 | 10,629,000 | 10,297,000 | 10,496,500 | 9,007,000 | 8,907,000 | 7,273,000 | 6,065,000 |
| EBITDA Margin | 8.1% | -0.71 | -0.77 | -0.83 | -0.91 | -1.04 | -1.11 | -1.15 | -1.14 | -1.09 | -1.01 | -1.01 | -1.08 | -1.47 | -1.90 | -2.11 | - | - | - | - | - | - |
| Interest Expenses | 0% | 1,000 | 1,000 | 2,000 | 1,000 | 25,500 | - | 29,000 | 26,000 | 83,500 | 70,000 | 95,000 | 118,000 | 143,000 | 181,000 | 215,000 | 248,000 | 287,500 | 318,000 | 340,000 | 348,000 | 386,000 |
| Income Taxes | -128.0% | -174,000 | 622,000 | 676,000 | 76,000 | 303,000 | -149,000 | -149,000 | -10,405,000 | 370,500 | -2,377,000 | 61,000 | 46,000 | 262,500 | 21,000 | 61,000 | 37,000 | 112,000 | 54,000 | 84,000 | 43,000 | 76,000 |
| Earnings Before Taxes | 18.2% | -46,465,000 | -56,773,000 | -58,480,000 | -41,748,000 | -50,823,000 | -60,666,000 | -60,817,000 | -55,968,000 | -40,901,500 | -42,414,000 | -37,858,000 | -32,854,000 | -24,055,500 | -28,186,000 | -31,707,000 | -55,601,000 | -31,069,000 | -27,862,000 | -25,849,000 | -22,596,000 | -19,726,000 |
| EBT Margin | 5.9% | -0.83 | -0.88 | -0.93 | -0.99 | -1.12 | -1.19 | -1.23 | -1.21 | -1.16 | -1.08 | -1.09 | -1.16 | -1.55 | -2.00 | -2.22 | - | - | - | - | - | - |
| Net Income | 19.4% | -46,243,000 | -57,395,000 | -59,156,000 | -41,824,000 | -51,115,000 | -60,517,000 | -60,668,000 | -45,563,000 | -41,242,000 | -40,037,000 | -37,919,000 | -32,900,000 | -24,318,000 | -28,207,000 | -31,768,000 | -55,638,000 | -31,181,000 | -27,916,000 | -25,933,000 | -22,639,000 | -19,802,000 |
| Net Income Margin | 6.2% | -0.83 | -0.89 | -0.93 | -0.99 | -1.07 | -1.13 | -1.15 | -1.13 | -1.15 | -1.07 | -1.09 | -1.16 | -1.55 | -2.00 | -2.23 | - | - | - | - | - | - |
| Free Cashflow | 17.3% | -23,097,000 | -27,921,000 | -53,341,000 | -65,894,000 | -17,729,000 | -74,767,000 | -74,310,000 | -59,436,000 | -42,892,000 | -34,902,000 | -32,950,000 | -28,561,000 | -27,427,000 | -26,316,000 | -61,408,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -4.2% | 776 | 810 | 854 | 910 | 961 | 980 | 1,022 | 786 | 702 | 725 | 677 | 700 | 399 | 408 | 324 | 192 | 187 | 207 | 140 | 164 | 116 |
| Current Assets | -4.8% | 424 | 446 | 489 | 542 | 596 | 624 | 664 | 385 | 546 | 577 | 608 | 634 | 335 | 345 | 260 | 129 | 160 | 183 | 121 | 147 | 96.00 |
| Cash Equivalents | -5.9% | 289 | 307 | 315 | 317 | 379 | 378 | 409 | 193 | 467 | 477 | 401 | 350 | 94.00 | 209 | 185 | 27.00 | 47.00 | 69.00 | 29.00 | 67.00 | 82.00 |
| Inventory | -11.8% | 32.00 | 36.00 | 40.00 | 45.00 | 39.00 | 43.00 | 45.00 | 40.00 | 32.00 | 21.00 | 16.00 | 13.00 | 12.00 | 13.00 | 11.00 | 7.00 | 7.00 | 5.00 | 4.00 | 6.00 | 6.00 |
| Net PPE | -6.4% | 132 | 141 | 147 | 145 | 139 | 127 | 92.00 | 65.00 | 44.00 | 38.00 | 32.00 | 27.00 | 25.00 | 24.00 | 23.00 | 21.00 | 21.00 | 20.00 | 15.00 | 14.00 | 12.00 |
| Goodwill | 0% | 86.00 | 86.00 | 86.00 | 86.00 | 86.00 | 86.00 | 86.00 | 84.00 | 22.00 | 23.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Liabilities | 0.1% | 153 | 153 | 150 | 164 | 172 | 159 | 158 | 160 | 121 | 115 | 63.00 | 62.00 | 63.00 | 59.00 | 60.00 | 89.00 | 35.00 | 31.00 | 25.00 | 26.00 | 27.00 |
| Current Liabilities | 0.7% | 73.00 | 73.00 | 72.00 | 84.00 | 91.00 | 93.00 | 85.00 | 80.00 | 63.00 | 55.00 | 40.00 | 37.00 | 36.00 | 31.00 | 30.00 | 58.00 | 30.00 | 25.00 | 19.00 | 19.00 | 19.00 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 2.00 | 3.00 | 4.00 | 4.00 | 5.00 | 6.00 | 7.00 | 7.00 |
| Shareholder's Equity | -5.2% | 623 | 658 | 704 | 746 | 789 | 821 | 863 | 626 | 581 | 610 | 614 | 638 | 336 | 349 | 264 | 103 | 152 | 176 | 115 | 139 | - |
| Retained Earnings | -4.7% | -1,033 | -986 | -929 | -870 | -828 | -777 | -716 | -656 | -610 | -569 | -529 | -491 | -458 | -434 | -405 | -374 | -318 | -287 | -259 | -233 | -210 |
| Additional Paid-In Capital | 0.7% | 1,657 | 1,645 | 1,633 | 1,617 | 1,620 | 1,599 | 1,581 | 1,282 | 1,191 | 1,179 | 1,143 | 1,129 | 795 | 783 | 670 | 477 | 470 | 463 | 375 | 372 | 9.00 |
| Shares Outstanding | 0.3% | 58.00 | 57.00 | 57.00 | 57.00 | 57.00 | 53.00 | 53.00 | 50.00 | 49.00 | 49.00 | 47.00 | 46.00 | 39.00 | 37.00 | 37.00 | 33.00 | 27.00 | 30.00 | 24.00 | - | - |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 11.6% | -20,704,000 | -23,412,000 | -44,288,000 | -54,070,000 | -1,267,000 | -34,125,000 | -42,340,000 | -46,653,000 | -34,803,000 | -27,960,000 | -24,549,000 | -24,932,000 | -25,202,000 | -23,468,000 | -58,671,000 | -34,914,000 | -23,358,000 | -22,082,000 | -20,813,000 | -21,684,000 | -16,696,000 |
| Share Based Compensation | 10.9% | 11,747,000 | 10,597,000 | 10,259,000 | -2,325,000 | 19,048,000 | 20,043,000 | 22,465,000 | 18,108,000 | 9,247,000 | 9,176,000 | 11,553,000 | 7,022,000 | 5,131,000 | 4,071,000 | 4,197,000 | 3,697,000 | 3,363,000 | 3,032,000 | 2,911,000 | 1,864,000 | 1,086,000 |
| Cashflow From Investing | -112.0% | -2,247,000 | 18,670,000 | 41,160,000 | -6,971,000 | 2,783,000 | 4,163,000 | -13,294,000 | -226,582,000 | 23,911,000 | 104,575,000 | 73,590,000 | -45,921,000 | -94,669,000 | -61,149,000 | 28,763,000 | 12,405,000 | -1,187,000 | -22,706,000 | -15,160,000 | -65,757,000 | 404,000 |
| Cashflow From Financing | 166.9% | 442,000 | -661,000 | 1,525,000 | -395,000 | 1,240,000 | -1,311,000 | 271,616,000 | -1,011,000 | 1,575,000 | -765,000 | 1,451,000 | 326,921,000 | 5,574,000 | 108,064,000 | 188,037,000 | 2,057,000 | 2,928,000 | 84,285,000 | -1,634,000 | 72,999,000 | 6,583,000 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
TWST Income Statement
2023-09-30Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||||
|---|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2021 | |||
| Statement of Comprehensive Income [Abstract] | |||||
| Revenues [1] | [1] | $ 245,109 | $ 203,565 | $ 132,333 | |
| Operating expenses: | |||||
| Cost of revenues | 155,380 | 119,330 | 80,620 | ||
| Research and development | 106,894 | 120,307 | 69,072 | ||
| Selling, general and administrative | 189,738 | 212,949 | 135,901 | ||
| Restructuring and other costs | 16,169 | 0 | 0 | ||
| Change in fair value of contingent considerations and holdbacks | (5,913) | (14,245) | (534) | ||
| Total operating expenses | 462,268 | 438,341 | 285,059 | ||
| Loss from operations | (217,159) | (234,776) | (152,726) | ||
| Interest income | 14,365 | 3,062 | 435 | ||
| Interest expense | (5) | (80) | (367) | ||
| Gain on deconsolidation of subsidiary | 0 | 4,607 | 0 | ||
| Other income (expense), net | (667) | (1,087) | (1,370) | ||
| Loss before income taxes | (203,466) | (228,274) | (154,028) | ||
| (Provision for) benefit from income taxes | (1,152) | 10,411 | 1,930 | ||
| Net loss attributable to common stockholders | (204,618) | (217,863) | (152,098) | ||
| Other comprehensive loss: | |||||
| Change in unrealized gain (loss) on investments | 1,510 | (1,594) | (14) | ||
| Foreign currency translation adjustment | (423) | (795) | 473 | ||
| Comprehensive loss | $ (203,531) | $ (220,252) | $ (151,639) | ||
| Net loss per share attributable to common stockholders—basic (in dollars per share) | $ (3.60) | $ (4.04) | $ (3.15) | ||
| Net loss per share attributable to common stockholders—diluted (in dollars per share) | $ (3.60) | $ (4.04) | $ (3.15) | ||
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares) | 56,885 | 53,885 | 48,251 | ||
| Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares) | 56,885 | 53,885 | 48,251 | ||
| |||||
TWST Balance Sheet
2023-09-30Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Sep. 30, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 286,470 | $ 378,687 |
| Short-term investments | 49,943 | 126,281 |
| Accounts receivable, net | 44,064 | 40,294 |
| Inventories | 32,063 | 39,307 |
| Prepaid expenses and other current assets | 11,716 | 11,914 |
| Total current assets | 424,256 | 596,483 |
| Property and equipment, net | 131,830 | 139,441 |
| Operating lease right-of-use assets | 71,531 | 74,948 |
| Goodwill | 85,811 | 85,811 |
| Intangible assets, net | 54,483 | 59,738 |
| Restricted cash, non-current | 2,811 | 1,572 |
| Other non-current assets | 5,681 | 3,385 |
| Total assets | 776,403 | 961,378 |
| Current liabilities: | ||
| Accounts payable | 14,052 | 20,092 |
| Accrued expenses | 10,754 | 10,169 |
| Accrued compensation | 25,818 | 27,023 |
| Current portion of operating lease liability | 14,896 | 13,642 |
| Other current liabilities | 7,803 | 19,737 |
| Total current liabilities | 73,323 | 90,663 |
| Operating lease liability, net of current portion | 79,173 | 81,270 |
| Other non-current liabilities | 475 | 60 |
| Total liabilities | 152,971 | 171,993 |
| Commitments and contingencies | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value — 100,000 and 100,000 shares authorized at September 30, 2023 and 2022, respectively; 57,557 and 56,523 shares issued and outstanding at September 30, 2023 and 2022, respectively | 0 | 0 |
| Additional paid-in capital | 1,657,222 | 1,619,644 |
| Accumulated other comprehensive loss | (756) | (1,843) |
| Accumulated deficit | (1,033,034) | (828,416) |
| Total stockholders’ equity | 623,432 | 789,385 |
| Total liabilities and stockholders’ equity | $ 776,403 | $ 961,378 |
| Â CEO | Dr. Emily Marine Leproust Ph.D. |
|---|---|
| Â WEBSITE | www.twistbioscience.com |
| Â EMPLOYEES | 989 |